<code id='5DA399A55C'></code><style id='5DA399A55C'></style>
    • <acronym id='5DA399A55C'></acronym>
      <center id='5DA399A55C'><center id='5DA399A55C'><tfoot id='5DA399A55C'></tfoot></center><abbr id='5DA399A55C'><dir id='5DA399A55C'><tfoot id='5DA399A55C'></tfoot><noframes id='5DA399A55C'>

    • <optgroup id='5DA399A55C'><strike id='5DA399A55C'><sup id='5DA399A55C'></sup></strike><code id='5DA399A55C'></code></optgroup>
        1. <b id='5DA399A55C'><label id='5DA399A55C'><select id='5DA399A55C'><dt id='5DA399A55C'><span id='5DA399A55C'></span></dt></select></label></b><u id='5DA399A55C'></u>
          <i id='5DA399A55C'><strike id='5DA399A55C'><tt id='5DA399A55C'><pre id='5DA399A55C'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:5876
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Vertex non
          Vertex non

          ScientistsChristinaFreyandPaulNegulescuworkinalabatVertexPharmaceuticalsinSanDiego.SandyHuffakerforS

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          After John Oliver segment, STAT readers share their opioid

          STATWhencomedian JohnOliver tookpharmacompaniestotask onhisHBOshowSundayfortheirmarketingofpowerfuln